Pancreatic Cancer Research

ResearcherNational Taiwan UniversityActive in the last 2 years

Sung‐Hsin Kuo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0054-887X; OpenAlex author ID A5035504048. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 15

  1. Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jfma.2025.02.035↗
  2. Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00262-024-03821-3↗
  3. Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.870406↗
  4. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2021.1973710↗
  5. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating N… Co-author DOI 10.1186/s12935-021-02143-z↗
  6. Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy. Last author DOI 10.3389/fonc.2021.730646↗
  7. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Co-author DOI 10.1016/j.jfma.2019.01.015↗
  8. S-1-Associated Hypertriglyceridemia in a Patient With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jop.19.00204↗
  9. Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer. Last author DOI 10.3390/jcm8081115↗
  10. A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.12790↗
  11. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine… Co-author DOI 10.1371/journal.pone.0180628↗
  12. Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. Last author DOI 10.1111/jgh.13395↗
  13. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. Last author DOI 10.3748/wjg.v22.i32.7275↗
  14. Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κB is associated with a poor prognosis of pancreatic cancer. Co-author DOI 10.1159/000353452↗
  15. Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. Co-author DOI 10.1159/000330817↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shih‐Hung Yang · 13 shared papers, 2011–2024 · strength 1.44
  2. Yu‐Wen Tien · 12 shared papers, 2011–2024 · strength 1.30
  3. Kun‐Huei Yeh · 8 shared papers, 2016–2026 · strength 1.16
  4. Ann‐Lii Cheng · 10 shared papers, 2011–2024 · strength 0.99
  5. Bang‐Bin Chen · 4 shared papers, 2020–2024 · strength 0.67
  6. Yan‐Shen Shan · 2 shared papers, 2024–2026 · strength 0.53
  7. Jhe‐Cyuan Guo · 5 shared papers, 2016–2020 · strength 0.45
  8. Chien‐Jui Huang · 1 shared paper, 2026 · strength 0.32
  9. Shih‐Hung Yang · 1 shared paper, 2026 · strength 0.32
  10. Li‐Yuan Bai · 2 shared papers, 2021–2022 · strength 0.31
  11. Ting‐Chun Kuo · 3 shared papers, 2016–2021 · strength 0.26
  12. Hsu Wu · 2 shared papers, 2016–2019 · strength 0.18
  13. Shih-Hung Yang · 1 shared paper, 2021 · strength 0.15
  14. Jason Chia‐Hsien Cheng · 1 shared paper, 2021 · strength 0.15
  15. Yi-Lun Chen · 1 shared paper, 2021 · strength 0.15
  16. Hsing-Wu Chen · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.